ADAR1 CAPITAL MANAGEMENT LLC
Q3 2026 Form 13-F
AUSTIN, TEXAS
CIK 0001940272
· CRD 299694
· SEC-registered investment adviser
$2.3B Reported Value Total
ADAR1 CAPITAL MANAGEMENT, LLC reports 8 total accounts under management (AUM). There are 8 discretionary accounts valued at $1,675,126,109, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
2 funds
· $1.3B gross asset value
Hedge Fund: $1.3B
Source: Form ADV filed 2026-03-31
Reported value
$2.3B
Quarter over quarter
-6.9%
Holdings
261
Top-10 concentration
38.7%
Key People
Form ADV owners & control persons
Daniel Pawel Schneeberger
MANAGING PARTNER
Stuart Knox Graham
COO
Stephen Thomas Scipione
HEAD OF OPERATIONS, CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2026 13F record
Q3 2026 13F filing summary
| Period of report | September 30, 2026 |
|---|---|
| Filed | November 16, 2026 |
| Form | 13F-HR |
| Reported value | $2.3B |
| Positions | 261 |
| Change in reported value | +7.5% |
| New positions | 43 |
| Exited positions | 42 |
| Position turnover | 28.1% |
| Top-10 concentration | 38.7% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
261 | $2.3B |
|
Q2 2026 13F
Filed Aug 14, 2026
|
262 | $2.2B |
|
Q1 2026 13F
Filed May 18, 2026
|
290 | $1.7B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
249 | $1.4B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
197 | $1.1B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
199 | $652.1M |
|
Q1 2025 13F
Filed May 15, 2025
|
192 | $538.7M |
|
Q4 2024 13F
Filed Feb 13, 2025
|
195 | $500.4M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
258 | $614.9M |
|
Q2 2024 13F
Filed Aug 13, 2024
|
245 | $529.7M |
|
Q1 2024 13F
Filed May 15, 2024
|
239 | $440.8M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
150 | $279.8M |
Top 20 holdings · Q3 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ABVX ABIVAX SA | $203.1M | 8.65% |
| 2 | SPY STATE STR SPDR S&P 500 ETF T | $135.5M | 5.77% |
| 3 | PTGX PROTAGONIST THERAPEUTICS INC | $134.0M | 5.71% |
| 4 | ROIV ROIVANT SCIENCES LTD | $112.6M | 4.79% |
| 5 | ZLAB ZAI LAB LTD | $89.1M | 3.79% |
| 6 | IMVT IMMUNOVANT INC | $71.5M | 3.04% |
| 7 | XENE XENON PHARMACEUTICALS INC | $43.2M | 1.84% |
| 8 | DNLI DENALI THERAPEUTICS INC | $42.8M | 1.82% |
| 9 | BOXX EA SERIES TRUST | $39.9M | 1.7% |
| 10 | SEPN SEPTERNA INC | $38.1M | 1.62% |
| 11 | AGIO AGIOS PHARMACEUTICALS INC | $37.9M | 1.61% |
| 12 | AURA AURA BIOSCIENCES INC | $33.8M | 1.44% |
| 13 | VKTX VIKING THERAPEUTICS INC | $33.7M | 1.44% |
| 14 | CYTK CYTOKINETICS INC | $30.4M | 1.29% |
| 15 | INSM INSMED INC | $26.2M | 1.12% |
| 16 | FRNM FREENOME INC | $25.9M | 1.1% |
| 17 | CLDX CELLDEX THERAPEUTICS INC NEW | $25.9M | 1.1% |
| 18 | AVR ANTERIS TECHNOLOGIES GLOBAL | $25.2M | 1.07% |
| 19 | BBIO BRIDGEBIO PHARMA INC | $25.0M | 1.06% |
| 20 | PRAX PRAXIS PRECISION MEDICINES I | $24.7M | 1.05% |
Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.